Biocad

This study tests a new medicine called BCD-281 in people with relapsing-remitting multiple sclerosis (RRMS). The goal is to see if it reduces brain lesions and relapse rates better than the current standard drug. About 292 adults aged 18-55 with mild to moderate disability are be…

This phase 3 trial is testing a single dose of ANB-002, a gene therapy that delivers a working copy of the FIX gene, in 24 adults with hemophilia B. The goal is to see if it can reduce bleeding episodes compared to regular preventive factor IX infusions. Participants will be foll…

This study tests a new drug, BCD-261, in 198 adults with moderate to severe ulcerative colitis who haven't improved with standard treatments. Participants receive one of three doses of BCD-261 or a placebo as an injection. The goal is to see if the drug can reduce inflammation an…

This study tests a new drug called BCD-261 in 204 adults with moderate to severe active Crohn's disease who haven't improved with standard treatments. Participants receive either a low, medium, or high dose of BCD-261 or a placebo by injection. The goal is to see if the drug can …

This study tests a new biosimilar drug called BCD-057, which is a copy of the arthritis medication Humira. It will involve 444 healthy men aged 18-45 who receive a single injection of either BCD-057 or Humira. The goal is to see if the body processes the two drugs similarly and t…